Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obliterative Bronchiolitis Clear all
Recruiting No phase listed Observational

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511
View directory record Official record
Conditions
cGVHD
Interventions
Non-Interventional
Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

NCT00815919
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
bortezomib, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

Evaluation of the Safety and Clinical Performance of the Connected Catheter Study

NCT05330598
View directory record Official record
Conditions
Urinary Retention, Chronic
Interventions
Connected Catheter
Device
Lead sponsor
Spinal Singularity
Industry
Eligibility
22 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Downey, California • Inglewood, California • Murrieta, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation

NCT02935465
View directory record Official record
Conditions
Chronic, Non-neuropathic Back Pain
Interventions
Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT04362501
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
dupilumab, placebo
Biological · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 1, 2026, 1:19 PM EDT
Withdrawn Early Phase 1 Interventional

Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence

NCT03845322
View directory record Official record
Conditions
Hematoma, Subdural, Chronic
Interventions
Curcumin Pill, Placebo pills
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

NCT03716505
View directory record Official record
Conditions
Migraine Disorders
Interventions
gammaCore Sapphire active, gammaCore Sapphire Sham
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 1, 2026, 1:19 PM EDT
Active, not recruiting No phase listed Observational

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

NCT05250037
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Home spirometry, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
8 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Completed No phase listed Observational

Popcorn Lung: the Discovery of a New Disease

NCT00027235
View directory record Official record
Conditions
Lung Diseases, Interstitial, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 1:19 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

NCT05654922
View directory record Official record
Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
ARINA-1, Standard of care only
Drug · Other
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dexamethasone Solution and Dexamethasone in Mucolox™

NCT04540133
View directory record Official record
Conditions
Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
Interventions
dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Not applicable Interventional Results available

Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE

NCT01775735
View directory record Official record
Conditions
Migraine Disorders
Interventions
Occipital nerve stimulator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Valencia, California • Chicago, Illinois • Shreveport, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

NCT04039347
View directory record Official record
Conditions
Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome
Interventions
Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

NCT01600053
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide
Drug
Lead sponsor
Thomas Kipps
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 1, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional

Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease

NCT06458127
View directory record Official record
Conditions
Chronic Graft-versus-host Disease, Chronic GVHD, cGVHD
Interventions
Tele-palliative care visit
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 1:19 PM EDT
Completed No phase listed Observational

A Study of Factors That Affect Long-Term Kidney Transplant Function

NCT00270712
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
3,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions
etanercept
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

NCT03337620
View directory record Official record
Conditions
Headache, Migraine
Interventions
Tx360
Device
Lead sponsor
Tian Medical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
New Haven, Connecticut • Stamford, Connecticut • Fort Gordon, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 1, 2026, 1:19 PM EDT
Completed No phase listed Observational

Brain Markers Predicting Reading Recovery After Stroke

NCT03845686
View directory record Official record
Conditions
Left-Hemisphere Stroke
Interventions
Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Diagnostic Test
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 1, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT03315741
View directory record Official record
Conditions
Bronchiolitis Obliterans, Graft Vs Host Disease
Interventions
Pirfenidone 267 MG [Esbriet]
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 1, 2026, 1:19 PM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 1, 2026, 1:19 PM EDT